# Concept: Remaining amortisation period of Research and development expense for bioindustry

## Bilingual Labels
- **EN**: Remaining amortisation period of Research and development expense for bioindustry
- **KO**: 잔여상각기간, 연구개발비, 바이오 제약

- **ID**: dart:RemainingAmortisationPeriodOfResearchAndDevelopmentExpenseForBioindustry

## Reported Numerical Facts

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-01-01 to 2024-12-31**
  - **Value**: 9년
- **Period: 2025-01-01 to 2025-03-31**
  - **Value**: 8년

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-01-01 to 2024-12-31**
  - **Value**: 9년
- **Period: 2025-01-01 to 2025-03-31**
  - **Value**: 8년

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-01-01 to 2024-12-31**
  - **Value**: -
- **Period: 2025-01-01 to 2025-03-31**
  - **Value**: -

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-01-01 to 2024-12-31**
  - **Value**: -
- **Period: 2025-01-01 to 2025-03-31**
  - **Value**: -

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-01-01 to 2024-12-31**
  - **Value**: 7년
- **Period: 2025-01-01 to 2025-03-31**
  - **Value**: 7년

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-01-01 to 2024-12-31**
  - **Value**: 5년
- **Period: 2025-01-01 to 2025-03-31**
  - **Value**: 5년

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-01-01 to 2024-12-31**
  - **Value**: -
- **Period: 2025-01-01 to 2025-03-31**
  - **Value**: -

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-01-01 to 2024-12-31**
  - **Value**: -
- **Period: 2025-01-01 to 2025-03-31**
  - **Value**: -

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2025-01-01 to 2025-03-31**
  - **Value**: 6년

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-01-01 to 2024-12-31**
  - **Value**: 12년
- **Period: 2025-01-01 to 2025-03-31**
  - **Value**: 12년

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-01-01 to 2024-12-31**
  - **Value**: 12년
- **Period: 2025-01-01 to 2025-03-31**
  - **Value**: 12년

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-01-01 to 2024-12-31**
  - **Value**: -
- **Period: 2025-01-01 to 2025-03-31**
  - **Value**: -

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-01-01 to 2024-12-31**
  - **Value**: -
- **Period: 2025-01-01 to 2025-03-31**
  - **Value**: -

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-01-01 to 2024-12-31**
  - **Value**: 14년
- **Period: 2025-01-01 to 2025-03-31**
  - **Value**: 14년

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-01-01 to 2024-12-31**
  - **Value**: 14년
- **Period: 2025-01-01 to 2025-03-31**
  - **Value**: 14년

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-01-01 to 2024-12-31**
  - **Value**: -
- **Period: 2025-01-01 to 2025-03-31**
  - **Value**: -

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-01-01 to 2024-12-31**
  - **Value**: -
- **Period: 2025-01-01 to 2025-03-31**
  - **Value**: -

### **Context (Labels): Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-01-01 to 2024-12-31**
  - **Value**: -
- **Period: 2025-01-01 to 2025-03-31**
  - **Value**: -

## Accounting Standard References
- **Standard**: 제약․바이오 기업의 연구개발비 회계처리 관련 감독지침 nan, Paragraph: nan

---
*Source Document: entity00413046_2025-03-31.xbrl*
## Embeddable Text (for FAISS)
```text
Concept: Remaining amortisation period of Research and development expense for bioindustry
Bilingual Labels
 EN: Remaining amortisation period of Research and development expense for bioindustry
 KO: 잔여상각기간, 연구개발비, 바이오 제약
 ID: dart:RemainingAmortisationPeriodOfResearchAndDevelopmentExpenseForBioindustry
Reported Numerical Facts
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20240101 to 20241231
   Value: 9년
 Period: 20250101 to 20250331
   Value: 8년
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20240101 to 20241231
   Value: 9년
 Period: 20250101 to 20250331
   Value: 8년
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20240101 to 20241231
   Value: 
 Period: 20250101 to 20250331
   Value: 
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20240101 to 20241231
   Value: 
 Period: 20250101 to 20250331
   Value: 
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20240101 to 20241231
   Value: 7년
 Period: 20250101 to 20250331
   Value: 7년
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20240101 to 20241231
   Value: 5년
 Period: 20250101 to 20250331
   Value: 5년
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20240101 to 20241231
   Value: 
 Period: 20250101 to 20250331
   Value: 
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20240101 to 20241231
   Value: 
 Period: 20250101 to 20250331
   Value: 
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20250101 to 20250331
   Value: 6년
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20240101 to 20241231
   Value: 12년
 Period: 20250101 to 20250331
   Value: 12년
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20240101 to 20241231
   Value: 12년
 Period: 20250101 to 20250331
   Value: 12년
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20240101 to 20241231
   Value: 
 Period: 20250101 to 20250331
   Value: 
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20240101 to 20241231
   Value: 
 Period: 20250101 to 20250331
   Value: 
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20240101 to 20241231
   Value: 14년
 Period: 20250101 to 20250331
   Value: 14년
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20240101 to 20241231
   Value: 14년
 Period: 20250101 to 20250331
   Value: 14년
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20240101 to 20241231
   Value: 
 Period: 20250101 to 20250331
   Value: 
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20240101 to 20241231
   Value: 
 Period: 20250101 to 20250331
   Value: 
Context (Labels): Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20240101 to 20241231
   Value: 
 Period: 20250101 to 20250331
   Value: 
Accounting Standard References
 Standard: 제약․바이오 기업의 연구개발비 회계처리 관련 감독지침 nan, Paragraph: nan
Source Document: entity00413046_20250331.xbrl
```